Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pelthos Therapeutics (PTHS) Income from Continuing Operations (2024 - 2025)

Pelthos Therapeutics has reported Income from Continuing Operations over the past 2 years, most recently at 21664000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 21664000.0 for Q4 2025, down 1024.82% from a year ago — trailing twelve months through Dec 2025 was 43318550.0 (down 444.55% YoY), and the annual figure for FY2025 was 43319000.0, down 444.55%.
  • Income from Continuing Operations for Q4 2025 was 21664000.0 at Pelthos Therapeutics, down from 16238000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for PTHS hit a ceiling of 1695000.0 in Q3 2024 and a floor of 21664000.0 in Q4 2025.